Evofem Biosciences Executives
EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem Biosciences employs about 119 people. The company is managed by 6 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 19.83 employees per reported executive. Analysis of Evofem Biosciences' management performance can provide insight into the firm performance.
Justin File Executive Chief Officer |
Katherine Atkinson Insider Chief Officer |
Evofem |
Evofem Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (1.2475) % which means that it has lost $1.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8727) %, meaning that it created substantial loss on money invested by shareholders. Evofem Biosciences' management efficiency ratios could be used to measure how well Evofem Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Evofem Biosciences Workforce Comparison
Evofem Biosciences is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 483. Evofem Biosciences totals roughly 119 in number of employees claiming about 25% of equities under Health Care industry.
Evofem Biosciences Notable Stakeholders
An Evofem Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evofem Biosciences often face trade-offs trying to please all of them. Evofem Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evofem Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Justin File | Chief Officer | Profile | |
Katherine Atkinson | Chief Officer | Profile | |
Saundra Pelletier | Pres Chair | Profile | |
Amy Raskopf | VP Relations | Profile | |
Kathy GalloDoyle | VP Sales | Profile | |
Karina Fedasz | Head Devel | Profile |
About Evofem Biosciences Management Performance
The success or failure of an entity such as Evofem Biosciences often depends on how effective the management is. Evofem Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evofem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evofem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 119 people.
The data published in Evofem Biosciences' official financial statements typically reflect Evofem Biosciences' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Evofem Biosciences' quantitative information. For example, before you start analyzing numbers published by Evofem accountants, it's essential to understand Evofem Biosciences' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.
Evofem Biosciences Workforce Analysis
Traditionally, organizations such as Evofem Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evofem Biosciences within its industry.Evofem Biosciences Manpower Efficiency
Return on Evofem Biosciences Manpower
Revenue Per Employee | 69.3K | |
Revenue Per Executive | 1.4M | |
Net Loss Per Employee | 1.7M | |
Net Loss Per Executive | 34.2M | |
Working Capital Per Employee | 31.7K | |
Working Capital Per Executive | 629.6K |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |